- Previous close
0.7200 - Open
0.6895 - Bid 0.4549 x 100
- Ask 0.7642 x 200
- Day's range
0.5810 - 0.7200 - 52-week range
0.1970 - 6.7800 - Volume
1,438,341 - Avg. Volume
8,525,485 - Market cap (intra-day)
6.486M - Beta (5Y monthly) 1.04
- PE ratio (TTM)
-- - EPS (TTM)
-5.2800 - Earnings date --
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
--
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
scisparc.com3
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
Recent news: SPRC
View more
Performance overview: SPRC
Trailing total returns as of 17/01/2025, which may include dividends or other distributions. Benchmark is .
YTD return
1-year return
3-year return
5-year return
Compare to: SPRC
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: SPRC
View moreValuation measures
Market cap
6.49M
Enterprise value
3.99M
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
1.23
Price/book (mrq)
0.94
Enterprise value/revenue
2.28
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-38.85%
Return on equity (ttm)
-85.91%
Revenue (ttm)
1.75M
Net income avi to common (ttm)
-5.68M
Diluted EPS (ttm)
-5.2800
Balance sheet and cash flow
Total cash (mrq)
2.56M
Total debt/equity (mrq)
0.74%
Levered free cash flow (ttm)
-3.97M